Akebia Therapeutics Statistics
Want to see AKBA full AI Analyst Report?
Akebia Therapeutics (AKBA) Stock Statistics & Valuation Metrics
Total Valuation
Akebia Therapeutics has a market cap or net worth of $138.28M. The enterprise value is $311.77M.
- Market Cap
- $138.28M
- Enterprise Value
- $311.77M
Share Statistics
Akebia Therapeutics has 277,663,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 277,663,880
- Owned by Insiders
- 2.88%
- Owned by Institutions
- 29.18%
Financial Efficiency
Akebia Therapeutics’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is 9.26%.
- Return on Equity (ROE)
- -0.16
- Return on Assets (ROA)
- -0.01
- Return on Invested Capital (ROIC)
- 9.26%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 1.22M
- Profits Per Employee
- -27.55K
- Employee Count
- 194
- Asset Turnover
- 0.63
- Inventory Turnover
- 2.53
Valuation Ratios
The current PE Ratio of Akebia Therapeutics is -2.96. Akebia Therapeutics’s PEG ratio is 0.01.
- PE Ratio
- -2.96
- PS Ratio
- 0.67
- PB Ratio
- 6.45
- Price to FCF
- 9.46
- Price to Operating Cash Flow
- 8.32
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Akebia Therapeutics had revenue of 236.20M and earned -5.34M in profits. Earnings per share was -0.02.
- Revenue
- 236.20M
- Gross Profit
- 196.73M
- Operating Income
- 23.50M
- Pretax Income
- -3.72M
- Net Income
- -5.34M
- EBITDA
- 21.73M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was 15.78M and capital expenditures -1.92M, giving a free cash flow of 13.92M billion.
- Operating Cash Flow
- 15.78M
- Free Cash Flow
- 13.92M
- Free Cash Flow per Share
- 0.05
Dividends & Yields
Akebia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 10.58%
- Earnings Yield
- -33.94%
Stock Price Statistics
- Beta
- 0.84
- 52-Week Price Change
- -73.07%
- 50-Day Moving Average
- 0.78
- 200-Day Moving Average
- 1.10
- Relative Strength Index (RSI)
- 35.99
- Average Volume (3m)
- 8.22M
Important Dates
Akebia Therapeutics upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Akebia Therapeutics as a current ratio of 1.13, with Debt / Equity ratio of 663.29%
- Current Ratio
- 1.13
- Quick Ratio
- 1.04
- Debt to Market Cap
- 0.52
- Net Debt to EBITDA
- 1.45
- Interest Coverage Ratio
- 0.97
Taxes
In the past 12 months, Akebia Therapeutics has paid 1.62M in taxes.
- Income Tax
- 1.62M
- Effective Tax Rate
- -0.44
Enterprise Valuation
Akebia Therapeutics EV to EBITDA ratio is -0.92, with an EV/FCF ratio of 2.36.
- EV to Sales
- 0.17
- EV to EBITDA
- -0.92
- EV to Free Cash Flow
- 2.36
- EV to Operating Cash Flow
- 2.09
Balance Sheet
Akebia Therapeutics has $159.25M in cash and marketable securities with $60.49M in debt, giving a net cash position of $98.76M billion.
- Cash & Marketable Securities
- $159.25M
- Total Debt
- $60.49M
- Net Cash
- $98.76M
- Net Cash Per Share
- $0.36
- Tangible Book Value Per Share
- -$0.14
Margins
Gross margin is 78.89%, with operating margin of -15.74%, and net profit margin of -22.60%.
- Gross Margin
- 78.89%
- Operating Margin
- -15.74%
- Pretax Margin
- -21.90%
- Net Profit Margin
- -22.60%
- EBITDA Margin
- -18.05%
- EBIT Margin
- -18.68%
Analyst Forecast
The average price target for Akebia Therapeutics is $3.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $3.88
- Price Target Upside
- 717.51% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- -12.38%
- EPS Growth Forecast
- -118.99%
Scores
- Smart Score
- 3
- AI Score
- 45
